Neuropsychiatric disorders, such as schizophrenia, depression, anxiety or dementia are common and cause an enormous emotional and economic burden to patients, relatives, caregivers, and to the society.
Unfortunately, currently available drug treatments are far from satisfactory. Moreover, virtually all of these drugs are molecules (or chemically modified versions) discovered by chance several decades ago.
The failure to identify novel drugs has led major pharmaceutical companies to disengage from research and drug-discovery programs related to neuropsychiatric disorders (Nature 480, 161-162, 2011). One of the reasons for this failure is that there are no good animal models for neuropsychiatric disorders.
The discrepancy between the urgent need for improved therapeutic compounds along with their large market potential on the one hand, and the current lack of significant development of novel and improved drugs on the other, warrants alternative strategies aimed at identifying druggable targets related to neuropsychiatric disease.
In addition to our in-house activities dedicated at identifying new drug targets, we offer services in the following areas
Gene identification for pharmacogenetic purposes
validation and specification
GeneGuide is a spin-off company of the University of Basel, founded 2013, and directed by the two founders
Dominique de Quervain, M.D., is a full Professor at the Faculty of Medicine & Faculty of Psychology and Director of the Division of Cognitive Neuroscience, University of Basel, Switzerland. He is an expert in the fields of stress, brain imaging, and clinical trials.
Andreas Papassotiropoulos, M.D., is a full Professor at the Faculty of Medicine & Faculty of Psychology and Director of the Division of Molecular Neuroscience, University of Basel, Switzerland. He is an expert in the field of human genetics with a particular focus on psychiatry and neuroscience.
In 2019 MindGuide has been founded. MindGuide is a Division of GeneGuide and uses immersive technologies including next generation virtual reality and augmented reality to reduce anxiety, treat phobias and increase stress resilience.